EW250516P42500
- 0.00
- 0.000.00%
Edwards Lifesciences Newsroom
Research Alert: CFRA Reiterates Buy View On Shares Of Edwards Lifesciences Corporation
Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78
Sector Update: Health Care Stocks Steady Pre-Bell Thursday
Research Alert: Ew Reports Q1 Results, Posting Strong Operating Margins
New Analyst Forecast: $EW Given 'Overweight' Rating
Edwards Lifesciences Is Maintained at Neutral by Baird
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Resmed (RMD) and Thermo Fisher (TMO)
Edwards Lifesciences Analyst Ratings
Piper Sandler Upgrades Edwards Lifesciences(EW.US) to Buy Rating, Raises Target Price to $80
Express News | Edwards Lifesciences Shares Rise 4.3% Premarket After Co Lifts 2025 Sales Forecast
Express News | Edwards Lifesciences Corp : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $80 From $73
TD Cowen Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $75
Edwards Lifesciences: Hold Rating Amid Strong Q1 Results and Future Challenges
Earnings Call Summary | Edwards Lifesciences(EW.US) Q1 2025 Earnings Conference
Express News | Edwards Lifesciences Exec Says Tariffs Expected to Impact EPS by About 5 Cents in 2025, Expects Bigger Impact in 2026 - Conf Call
Edwards Lifesciences Q1 Adjusted Earnings, Sales Rise; Provides Q2 Guidance
Edwards Lifesciences Non-GAAP EPS of $0.64 Beats by $0.04, Revenue of $1.41B Beats by $10M
Express News | Corrected-Edwards Lifesciences Corp: Reaffirming FY Adjusted EPS of $2.40 to $2.50, Including Estimated Jenavalve Dilution and Tariff Impact (Adds Dropped Period)